Allogene Therapeutics
Julie Kang is an experienced professional in clinical operations, currently serving as Associate Director of Clinical Operations at Allogene Therapeutics since January 2025. Prior roles include Senior Manager of Clinical Operations at ACELYRIN, INC. from May 2022 to December 2024, and Sr. Clinical Trial Manager at Atara Biotherapeutics from August 2019 to May 2022. Julie's career also includes significant positions at Array BioPharma as Clinical Program Manager/Senior Clinical Research Manager, Kforce as Clinical Study Manager/Manager Clinical Affairs, and Amgen as Clinical Research Associate and Research Associate. Julie holds a Bachelor of Science degree in Microbiology from the University of Arizona.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.